# US 2021/0172015 A1 · Immune profiling by primer extension target enrichment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0172015 A1
- Document ID: US20210172015A1
- Status: Published application
- Kind: A1
- Application number: 16/996,733
- Filed: 2020-08-18
- Published: 2021-06-10
- Earliest claimed: 2016-06-01
- Assignees: Roche Sequencing Solutions, Inc.
- Applicants: Roche Sequencing Solutions, Inc
- Inventors: Jan Berka; Carolina Dallett; Richard Dannebaum; Brian Godwin; Seoyoung Kim; Jainee Lewis; Khai Luong; Sedide Ozturk; Joseph Platzer; Florian Rubelt; Dilduz Telman
- Web page: https://patentgrep.com/patent/US20210172015A1

## CPC

- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- C40B 50/06: Biochemical methods, e.g. using enzymes or whole viable microorganisms
- C12N 15/1065: {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- C12Q 1/68: involving nucleic acids
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Methods and compositions are described herein for primer extension target enrichment of immune receptor (BCR or TCR) sequences.

## Claims

### Claim 1

A method for enriching a sample for a plurality of structurally different target polynucleotides comprising an immune gene sequence the method comprising:
a) contacting a sample with a plurality of immune cell receptor V gene specific primers, each primer including from 5′ to 3′: [5′-Phos], [SPLINT1], [BARCODE], and [V], wherein: [5′-Phos] is a 5′ phosphate; [SPLINT] is a first adaptor sequence; [BARCODE] is a unique molecular identifier barcode; and [V] is a sequence capable of hybridizing to an immune cell receptor V gene;
b) hybridizing and extending the V gene specific primers to form a plurality of first double-stranded primer extension products;
c) contacting the sample with an exonuclease to remove unhybridized V gene specific primers from the first double stranded primer extension products;
d) contacting the sample with a plurality of immune cell receptor J gene specific primers, each primer including from 5′ to 3′: [5′-Phos], [SPLINT2], and [J], wherein: [5′-Phos] is a 5′ phosphate; [SPLINT2] is a second adaptor sequence; and [J] is a sequence capable of hybridizing to an immune cell receptor J gene; and further contacting the sample with a first universal primer capable of hybridizing to the first adaptor sequence;
e) hybridizing and extending the J gene specific primers and the first universal primer to form a plurality of second double-stranded primer extension products;
f) contacting the sample with an exonuclease to remove unhybridized J gene specific primers and first universal primer from the second double-stranded primer extension products;
g) contacting the sample with first and second universal primers capable of hybridizing to the first and second adaptor sequences;
h) amplifying the plurality of second double-stranded primer extension products thereby enriching the plurality of structurally different target polynucleotides comprising an immune gene sequence.

### Claim 2 (depends on 1)

The method of claim 1, wherein the immune genes comprise one or more of T-cell receptor alpha (TCRA), T-cell receptor beta (TCRB), T-cell receptor gamma (TCRG), T-cell receptor delta (TCRD), Immunoglobulin heavy chain (IGH), Immunoglobulin light chain-kappa (IGK) and Immunoglobulin light lambda (IGL).

### Claim 3 (depends on 1)

The method of claim 1, wherein the plurality of V gene specific primers and the plurality of J gene specific primers include primers from Table 2a.

### Claim 4 (depends on 1)

The method of claim 1, wherein hybridizing in steps b) and/or e) comprises one or more cycles of a step-wise temperature drop of two or more steps.

### Claim 5 (depends on 4)

The method of claim 4, wherein hybridizing in steps b) and/or e) comprises 20 cycles of temperature change from 60° C. to 57.5° C. and to 55° C.

### Claim 6 (depends on 1)

The method of claim 1, wherein hybridizing and extending in step e) comprises two or more cycles of duplex denaturation, primer annealing and primer extension.

### Claim 7 (depends on 6)

The method of claim 6, wherein primer annealing comprises one or more cycles of a step-wise temperature drop of two or more steps.

### Claim 8 (depends on 7)

The method of claim 7, wherein hybridizing and extending in step e) comprises 10 cycles temperature change from >90° C., to 60° C. to 57.5° C., to 55° C. and to 72° C.

### Claim 9 (depends on 1)

The method of claim 1, wherein the first and second universal primers in step g) comprise additional 5′sequences not present in the first and second adaptors.

### Claim 10 (depends on 9)

The method of claim 9, wherein the first universal primer in step d) does not comprise additional 5′sequences not present in the first adaptor.

### Claim 11 (depends on 1)

The method of claim 1, wherein the exonuclease in steps c) and/or f) is thermolabile.

### Claim 12 (depends on 11)

The method of claim 11, wherein the exonuclease is Exonuclease I.

### Claim 13 (depends on 1)

The method of claim 1, wherein extending in steps b) and/or e) is with a high-fidelity DNA polymerase.

### Claim 14 (depends on 1)

The method of claim 1, further comprising a purification step after steps c) and/or h).

### Claim 15 (depends on 1)

The method of claim 1, not having a purification step between steps f) and g).

### Claim 16 (depends on 15)

The method of claim 15, wherein the first and second universal primers comprise a modification preventing digestion of the primers with the exonuclease.

### Claim 17 (depends on 16)

The method of claim 16, wherein the primers comprise one or more nucleotides having a modification selected from: phosphorothioate (PS) bond, a 2′-O-methyl (2′OMe), a 2′-fluoride and Inverted ddT.

### Claim 18 (depends on 1)

The method of claim 1, wherein the V-gene specific primers, the J-gene specific primers and the first universal primer in step d) do not comprise a modification preventing digestion of the primers with the exonuclease.

### Claim 19 (depends on 1)

The method of claim 1, further comprising sequencing the plurality of structurally different target polynucleotides comprising an immune gene sequence.

### Claim 20

A method for contamination-reduced sequencing a plurality of structurally different target polynucleotides comprising an immune gene sequence the method comprising:
a) contacting a sample with a plurality of immune cell receptor V gene specific primers, each primer including from 5′ to 3′: [5′-Phos], [SPLINT1], [BARCODE], and [V], wherein: [5′-Phos] is a 5′ phosphate; [SPLINT] is a first adaptor sequence; [BARCODE] is a unique molecular identifier barcode (UMI); and [V] is a sequence capable of hybridizing to an immune cell receptor V gene;
b) hybridizing and extending the V gene specific primers to form a plurality of first double-stranded primer extension products;
c) contacting the sample with an exonuclease to remove unhybridized V gene specific primers from the first double stranded primer extension products;
d) contacting the sample with a plurality of immune cell receptor J gene specific primers, each primer including from 5′ to 3′: [5′-Phos], [SPLINT2], and [J], wherein: [5′-Phos] is a 5′ phosphate; [SPLINT2] is a second adaptor sequence; and [J] is a sequence capable of hybridizing to an immune cell receptor J gene; and further contacting the sample with a first universal primer capable of hybridizing to the first adaptor sequence;
e) hybridizing and extending the J gene specific primers and the first universal primer to form a plurality of second double-stranded primer extension products;
f) contacting the sample with an exonuclease to remove unhybridized J gene specific primers and first universal primer from the second double-stranded primer extension products;
g) contacting the sample with first and second universal primers capable of hybridizing to the first and second adaptor sequences;
h) amplifying the plurality of second double-stranded primer extension products thereby enriching the plurality of structurally different target polynucleotides comprising an immune gene sequence;
i) sequencing the plurality of structurally different target polynucleotides comprising an immune gene sequence to obtain a dataset of sequence reads;
j) grouping the sequence reads having an identical UMI into UMI families;
k) removing from the dataset UMI families with relative representation of less than 10%.

### Claim 21 (depends on 20)

The method of claim 20, wherein representation in step k) is less than 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1%.

### Claim 22 (depends on 20)

The method of claim 20, wherein the immune genes comprise one or more of T-cell receptor alpha (TCRA), T-cell receptor beta (TCRB), T-cell receptor gamma (TCRG), T-cell receptor delta (TCRD), Immunoglobulin heavy chain (IGH), Immunoglobulin light chain-kappa (IGK) and Immunoglobulin light chain-lambda (IGL).

### Claim 23 (depends on 20)

The method of claim 20, wherein the plurality of V gene specific primers and the plurality of J gene specific primers include primers from Table 2a.

### Claim 24 (depends on 20)

The method of claim 20, wherein hybridizing in steps b) and/or e) comprises one or more cycles of a step-wise temperature drop of two or more steps.

### Claim 25 (depends on 24)

The method of claim 24, wherein hybridizing in steps b) and/or e) comprises 20 cycles of temperature change from 60° C. to 57.5° C. and to 55° C.

### Claim 26 (depends on 20)

The method of claim 20, wherein hybridizing and extending in step e) comprises two or more cycles of duplex denaturation, primer annealing and primer extension.

### Claim 27 (depends on 26)

The method of claim 26, wherein primer annealing comprises one or more cycles of a step-wise temperature drop of two or more steps.

### Claim 28 (depends on 27)

The method of claim 27, wherein hybridizing and extending in step e) comprises 10 cycles temperature change from >90° C., to 60° C. to 57.5° C., to 55° C. and to 72° C.

### Claim 29 (depends on 20)

The method of claim 20, wherein the first and second universal primers in step g) comprise additional 5′sequences not present in the first and second adaptors.

### Claim 30 (depends on 29)

The method of claim 29, wherein the first universal primer in step d) does not comprise additional 5′sequences not present in the first adaptor.

### Claim 31 (depends on 20)

The method of claim 20, wherein the exonuclease in steps c) and/or f) is thermolabile.

### Claim 32 (depends on 31)

The method of claim 31, wherein the exonuclease is Exonuclease I.

### Claim 33 (depends on 20)

The method of claim 20, wherein extending in steps b) and/or e) is with a high-fidelity DNA polymerase.

### Claim 34 (depends on 20)

The method of claim 20, further comprising a purification step after steps c) and/or h).

### Claim 35 (depends on 20)

The method of claim 20, not having a purification step between steps f) and g).

### Claim 36 (depends on 35)

The method of claim 35, wherein the first and second universal primers comprise a modification preventing digestion of the primers with the exonuclease.

### Claim 37 (depends on 36)

The method of claim 36, wherein the primers comprise one or more nucleotides having a modification selected from: phosphorothioate (PS) bond, a 2′-O-methyl (2′OMe), a 2′-fluoride and Inverted ddT.

### Claim 38 (depends on 20)

The method of claim 20, wherein the V-gene specific primers, the J-gene specific primers and the first universal primer in step d) do not comprise a modification preventing digestion of the primers with the exonuclease.
